SOX9 and diffuse large B-cell lymphoma: Our previous findings showed that SOX9 was preferentially highly expressed in the germinal centre B‐cell‐like (GCB) DLBCL subtype harbouring an IGH/BCL2 translocation and serves as a biomarker that is significantly associated with poor prognosis and response to chemotherapeutics; however, the regulatory mechanism of SOX9 overexpression in this subset remains elusive.